Search Results - "Strijbis, E. M. M."

Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR by Noteboom, Samantha, van Nederpelt, D. R., Bajrami, A., Moraal, B., Caan, M. W. A., Barkhof, F., Calabrese, M., Vrenken, H., Strijbis, E. M. M., Steenwijk, M. D., Schoonheim, M. M.

“…Background and objectives Disability and cognitive impairment are known to be related to brain atrophy in multiple sclerosis (MS), but 3D-T1 imaging required…”
Get full text

Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial by Nauta, Ilse M., Kessels, Roy P. C., Bertens, Dirk, Stam, Cornelis J., Strijbis, Eva E. M., Hillebrand, Arjan, Fasotti, Luciano, Uitdehaag, Bernard M. J., Hulst, Hanneke E., Speckens, Anne E. M., Schoonheim, Menno M., de Jong, Brigit A.

“…Background Cognitive treatment response varies highly in people with multiple sclerosis (PwMS). Identification of mechanisms is essential for predicting…”
Get full text

Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial by Toorop, A.A., Wessels, M.H.J., Gelissen, L.M.Y., Hoitsma, E., Zeinstra, E.M.P.E., van Rooij, L.C., van Munster, C.E.P., Vennegoor, A., Mostert, J.P., Wokke, B.H.A., Kalkers, N.F., Hoogervorst, E.L.J., van Eijk, J.J.J., Roosendaal, C.M., Kragt, J.J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L.G.F., Kloosterziel, M.E., Arnoldus, E.P.J., van Dijk, G.W., Bouvy, W.H., Strijbis, E.M.M., van Oosten, B.W., de Jong, B.A., Lissenberg-Witte, B.I., Rispens, T., Uitdehaag, B.M.J., Killestein, J., van Kempen, Z.L.E.

“…Wearing-off symptoms during natalizumab treatment in multiple sclerosis are characterized by an increase of MS-related symptoms prior to natalizumab…”
Get full text

Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data by Noteboom, S., Strijbis, E.M.M., Coerver, E.M.E., Colato, E., van Kempen, Z.L.E., Jasperse, B., Vrenken, H., Killestein, J., Schoonheim, M.M., Steenwijk, M.D.

“…•Effect of high efficacy therapy on brain atrophy was investigated on clinical MRI.•Natalizumab slowed ventricular growth the most (1.1 %/year).•Patients…”
Get full text

Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis by Coerver, E.M.E., Bourass, A., Wessels, M.H.J., van Kempen, Z.L.E., Jasperse, M.M.S., Tonino, B.A.R., Barkhof, F., Mostert, J., Uitdehaag, B.M.J., Killestein, J., Strijbis, E.M.M.

“…•The most frequent reason for discontinuation of therapy was side effects.•Sixty percent of the participants showed disease activity after…”
Get full text

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? by van Kempen, Z.L.E., Wieske, L., Stalman, E.W., Kummer, L. Y. L, van Dam, P.J., Volkers, A.G., Boekel, L., Toorop, A.A., Strijbis, E.M.M., Tas, S.W., Wolbink, G.J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N.J.M., Steenhuis, M., Kuijpers, T.W., van Ham, S.M., Rispens, T., Eftimov, F., Killestein, J.

“…The objective of this study was to measure humoral responses after SARS-CoV-2 vaccination in MS patients treated with ocrelizumab (OCR) compared to MS patients…”
Get full text

Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosis by Molenaar, P.C.G., Strijbis, E.M.M., van Munster, C.E.P., Uitdehaag, B.M.J., Kalkers, N.F.

“…•The arm function in multiple sclerosis questionnaire (AMSQ) shows moderate correlations with established physician- and performance based outcome measures in…”
Get full text

The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis by van ‘t Hullenaar, C.A.A., Coerver, E., Kalkers, N.F., van Kempen, Z., Koch, M., Uitdehaag, B.M.J., Killestein, J., Strijbis, E.M.M.

“…Patient reported outcome measures (PROMs) are especially relevant in times of increased interest in telehealth but little is known about their relation to…”
Get full text

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis by Wiebenga, O T, Schoonheim, M M, Hulst, H E, Nagtegaal, G J A, Strijbis, E M M, Steenwijk, M D, Polman, C H, Pouwels, P J W, Barkhof, F, Geurts, J J G

“…Natalizumab treatment strongly affects relapsing-remitting multiple sclerosis, possibly by restraining white matter damage. This study investigated changes in…”
Get full text

Natalizumab discontinuation in a Dutch real-world cohort by Coerver, E.M.E., Wessels, M.H.J., van Lierop, Z.Y.G., van Kempen, Z.L.E., Killestein, J., Strijbis, E.M.M.

“…To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Data was collected from an ongoing…”
Get full text

Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain network by Nij Bijvank, J.A., Strijbis, E.M.M., Nauta, I.M., Kulik, S.D., Balk, L.J., Stam, C.J., Hillebrand, A., Geurts, J.J.G., Uitdehaag, B.M.J., van Rijn, L.J., Petzold, A., Schoonheim, M.M.

“…•Impaired eye movements in multiple sclerosis (MS) and functional connectivity (FC)•Eye movements related to altered FC of the oculomotor brain network.•Lower…”
Get full text

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab by Toorop, Alyssa A., van Lierop, Zoë Y.G., Strijbis, Eva E.M., Teunissen, Charlotte E., Petzold, Axel, Wattjes, Mike P., Barkhof, Frederik, de Jong, Brigit A., van Kempen, Zoé L.E., Killestein, Joep

“…To describe the disease course of carryover progressive multifocal leukoencephalopathy (PML) after switching from natalizumab to ocrelizumab in 2 patients with…”
Get full text

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No by Strijbis, EMM, Koch, MW, de Jong, BA

Get full text

The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis by Toorop, A.A., van Lierop, Z.Y.G.J., Strijbis, E.M.M., Teunissen, C.E., Barkhof, F., Uitdehaag, B.M.J., van Kempen, Z.L.E., Killestein, J.

“…•The wearing-off phenomenon is reported by more than half of patients with MS using ocrelizumab.•Only BMI was identified as a predicting factor.•The…”
Get full text

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients by van Lierop, ZYGJ, Toorop, AA, Coerver, EME, Willemse, EAJ, Strijbis, EMM, Kalkers, NF, Moraal, B, Barkhof, F, Teunissen, CE, Killestein, J, van Kempen, ZLE

“…Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our…”
Get full text